Suppression of bone metastatic castration-resistant prostate cancer cell growth by a suicide gene delivered by JC polyomavirus-like particles.
Journal
Gene therapy
ISSN: 1476-5462
Titre abrégé: Gene Ther
Pays: England
ID NLM: 9421525
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
09
02
2021
accepted:
09
07
2021
revised:
01
07
2021
medline:
23
6
2023
pubmed:
22
7
2021
entrez:
21
7
2021
Statut:
ppublish
Résumé
Prostate cancer is one of the most common cancers in men. The heterogeneity and mutations exhibited by prostate cancer cells often results in the progression to incurable metastatic castration-resistant prostate cancer (mCRPC). Our previous investigations demonstrated that the virus-like particles (VLPs) of JC polyomavirus (JCPyV) can deliver exogenous genes to prostate cancer cells for expression. JCPyV VLPs packaging pPSAtk (PSAtk-VLPs) possess the ability to transcriptionally target and selectively induce cytotoxicity in prostate cancer cells in vitro and in vivo, as pPSAtk can only express the thymidine kinase gene, a suicide gene, in androgen receptor-positive cells. To further investigate whether PSAtk-VLPs inhibit the growth of metastasized prostate cancer cells, we established an animal model of bone-metastatic prostate cancer to compare PSAtk-VLPs with leuprorelin acetate and enzalutamide, hormonal agents commonly used in clinical settings, and investigated the effectiveness of PSAtk-VLPs. In the present study, we observed that PSAtk-VLPs effectively inhibited the growth of prostate cancer cells that had metastasized to the bone in the metastatic animal model. In addition, PSAtk-VLPs showed a higher effectiveness than hormone therapy in this animal model study. These results suggest that PSAtk-VLPs may serve as a treatment option for mCRPC therapy in the future.
Identifiants
pubmed: 34285388
doi: 10.1038/s41434-021-00280-8
pii: 10.1038/s41434-021-00280-8
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
534-537Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: Cancer J Clin. 2019;69:7–34.
pubmed: 30620402
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. J Int du Cancer. 2015;136:E359–86.
doi: 10.1002/ijc.29210
van der Toom EE, Axelrod HD, de la Rosette JJ, de Reijke TM, Pienta KJ, Valkenburg KC. Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nat Rev Urol. 2019;16:7–22.
doi: 10.1038/s41585-018-0119-5
pubmed: 30479377
pmcid: 6324967
Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276–308.
doi: 10.1210/er.2002-0032
pubmed: 15082523
Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides. 1999;20:1247–62.
doi: 10.1016/S0196-9781(99)00130-8
pubmed: 10573298
Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004;351:1488–90.
doi: 10.1056/NEJMp048178
pubmed: 15470210
Nevedomskaya E, Baumgart SJ, Haendler B. Recent Advances in Prostate Cancer Treatment and Drug Discovery. Int J Mol Sci. 2018;19:1359–84.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–38.
doi: 10.1056/NEJMoa1315815
pubmed: 25184630
pmcid: 4201502
Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268–78.
doi: 10.1038/nrc2351
pubmed: 18337732
Pang S, Taneja S, Dardashti K, Cohan P, Kaboo R, Sokoloff M, et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Human Gene Ther. 1995;6:1417–26.
doi: 10.1089/hum.1995.6.11-1417
Lin MC, Wang M, Chou MC, Chao CN, Fang CY, Chen PL, et al. Gene therapy for castration-resistant prostate cancer cells using JC polyomavirus-like particles packaged with a PSA promoter driven-suicide gene. Cancer Gene Ther. 2019;26:208–15.
doi: 10.1038/s41417-019-0083-0
pubmed: 30692600
Kuroda S, Kubota T, Aoyama K, Kikuchi S, Tazawa H, Nishizaki M, et al. Establishment of a Non-Invasive Semi-Quantitative Bioluminescent Imaging Method for Monitoring of an Orthotopic Esophageal Cancer Mouse Model. PloS ONE. 2014;9:e114562.
doi: 10.1371/journal.pone.0114562
pubmed: 25493557
pmcid: 4262421
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: Cancer J Clin. 2018;68:7–30.
pubmed: 29313949
Mills IG. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer. 2014;14:187–98.
doi: 10.1038/nrc3678
pubmed: 24561445
Ciccarese C, Santoni M, Brunelli M, Buti S, Modena A, Nabissi M, et al. AR-V7 and prostate cancer: the watershed for treatment selection? Cancer Treat Rev. 2016;43:27–35.
doi: 10.1016/j.ctrv.2015.12.003
pubmed: 26827690
Naldini L. Gene therapy returns to centre stage. Nature. 2015;526:351–60.
doi: 10.1038/nature15818
pubmed: 26469046
Chen LS, Wang M, Ou WC, Fung CY, Chen PL, Chang CF, et al. Efficient gene transfer using the human JC virus-like particle that inhibits human colon adenocarcinoma growth in a nude mouse model. Gene Ther. 2010;17:1033–41.
doi: 10.1038/gt.2010.50
pubmed: 20410928
Chao CN, Huang YL, Lin MC, Fang CY, Shen CH, Chen PL, et al. Inhibition of human diffuse large B-cell lymphoma growth by JC polyomavirus-like particles delivering a suicide gene. J Transl Med. 2015;13:29.
doi: 10.1186/s12967-015-0389-0
pubmed: 25623859
pmcid: 4312600
Fang CY, Tsai YD, Lin MC, Wang M, Chen PL, Chao CN, et al. Inhibition of human bladder cancer growth by a suicide gene delivered by JC polyomavirus virus-like particles in a mouse model. J Urol. 2015;193:2100–6.
doi: 10.1016/j.juro.2015.01.084
pubmed: 25623749
Chao CN, Lin MC, Fang CY, Chen PL, Chang D, Shen CH, et al. Gene Therapy for Human Lung Adenocarcinoma Using a Suicide Gene Driven by a Lung-Specific Promoter Delivered by JC Virus-Like Particles. PloS ONE. 2016;11:e0157865.
doi: 10.1371/journal.pone.0157865
pubmed: 27322500
pmcid: 4913927
Chao CN, Yang YH, Wu MS, Chou MC, Fang CY, Lin MC, et al. Gene therapy for human glioblastoma using neurotropic JC virus-like particles as a gene delivery vector. Sci Rep. 2018;8:2213.
doi: 10.1038/s41598-018-19825-w
pubmed: 29396437
pmcid: 5797127
Khurana N, Kim H, Chandra PK, Talwar S, Sharma P, Abdel-Mageed AB, et al. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: advocating a potent pharmaceutical combination against castration-resistant prostate cancer. Oncol Rep. 2017;38:2774–86.
doi: 10.3892/or.2017.5932
pubmed: 28901514
pmcid: 5780030